Endocrinology & Diabetes ResearchISSN: 2470-7570

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Angelos Liontos Author

Subjects of specialization
COVID-19, Ketoacidosis, SARS-COV-2

Affiliation
Department of Infectious Diseases, University Hospital of Ioannina, Ioannina, Greece

Biography

Angelos Liontos Department of Infectious Diseases, University Hospital of Ioannina, Ioannina, Greece. His publications include: 1.Zheng, Z., et al., Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect, 2020. 81(2): p. e16-e25. 2.Jordan, R.E., P. Adab, and K.K. Cheng, Covid-19: risk factors for severe disease and death. Bmj, 2020. 368: p. m1198. 3.Wei, Y., et al., Clinical characteristics and outcomes of patients with diabetic ketoacidosis of different severity. Medicine (Baltimore), 2020. 99(45): p. e22838.


Publications

Case Report Open Access

Euglycemic Diabetic Ketoacidosis in a Patient with SARS-COV-2 Infection, a Stress Induced Complication or a Coronavirus Related Complication?

Author(s):

Sempastian Filippas-Ntekouan, Angelos Liontos, Fotios Barkas, Theodora Maniatopoulou, Revekka Konstantopoulou, Theodora Dimitriou, Georgia Manthou and Haralampos Milionis

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections have affected millions of persons around the globe since first described in December 2019. Coronavirus Disease (COVID-19) is primarily a respiratory tract infection and in severe cases may lead to pneumonia, acute respiratory distress syndrome and death. Diabetes mellitus comprises a serious comorbidity that has been associated with increased risk of adverse outcomes. In these patients, COVID-19 has been associated with increased risk of ketosis and ketoacidosis which is a life-threatening complication. Herein, we describe a case of a SARS-CoV-2 positive patient presenting with symptomatic euglycemic ketoacidosis soon after the initiation of a Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitor. Clinicians should be ... view moreĀ»

Abstract HTML PDF



Social Media


Google Scholars / Researchers Sites

GET THE APP